clinical data on the device/equivalent/ comparable device and also no state-of-the-art too?

This question is not very clear. As we mentioned in the presentation, the clinical data can be generated from subject device, equivalent device or comparable device. If you want to use a comparable device as well, you must summarize the clinical data for all devices to compose your CER.

Suggested Reading

Can products made from materials conforming to YY 0341.1 Appendix B be exempted from biological evaluation?
What factors may affect biocompatibility risk when using biological test data from similar devices for…
Do all medical devices require chemical characterization?
For subchronic systemic toxicity studied via implantation, what is the basis for determining the implantation…
What are the key focus areas in the evaluation of acute, subacute, subchronic, and chronic toxicity, and can…
How should the evaluation of new items in the endpoint table be considered after the implementation of the new…
Under what conditions can the extraction liquid of dressings be accepted after pH adjustment, centrifugation,…
GB/T 16886.11-2021 adds tests for subchronic systemic toxicity evaluation with dual-route exposure. Which…
When combining subchronic and implantation tests in one project, what factors need to be considered, and how can…
GB/T 16886.1-2022 includes implantation in the biological evaluation of dressings. How should implantation tests…
Why is the extraction period typically 24 hours in China for cytotoxicity testing?
How is the endotoxin limit for wound dressing products determined?

Clinical Data On The Device/equivalent/ Comparable Device And Also No State-of-the-art Too?

Suggested Reading